EU commits €330m to fusion and nuclear research as Europe races to close the fusion funding gap with the US and China

The European Commission has formally adopted the 2026-2027 Euratom Research and Training Programme Work Programme, allocating €330 million across fusion energy development and nuclear fission safety research in what represents the bloc’s most structured attempt to translate decades of publicly funded research into commercially competitive energy infrastructure. The programme directs €222 million toward fusion and €108 million toward fission-related innovation, safety, and skills, positioning the European Union as a public-sector counterweight to accelerating private fusion investment in the United States and state-directed capital deployment in China. The timing is deliberate: Brussels adopted the programme just days after European Commission President Ursula von der Leyen presented the EU’s Strategy on Small Modular Reactors at the Nuclear Energy Summit in Paris on 10 March 2026, signalling a broader nuclear policy reset at the highest level of the EU executive. For an institution that spent much of the last two decades downplaying nuclear energy in its climate narratives, this is a material shift in strategic posture.

Why is the European Commission investing €222 million in fusion energy in 2026 and what does it mean for grid delivery timelines?

The fusion allocation is the single largest component of the Euratom programme and reflects a structural reorientation in how the European Union approaches fusion policy. Until now, the primary vehicle for EU fusion investment was EUROfusion, a consortium of research institutions focused on fundamental plasma science and the EU’s contribution to ITER, the multinational experimental reactor under construction in southern France. The new programme does not abandon that scientific foundation, but it supplements it with something the EU has largely lacked: a mechanism to build a commercially oriented European fusion industry.

The centrepiece of the fusion allocation is the establishment of a new European Public-Private Partnership for Fusion Energy, which will issue the first calls under its framework as part of this two-year programme. The purpose is to de-risk private investment in fusion technologies, accelerate the development of commercially viable reactor designs, and strengthen what the Commission describes as a European fusion supply chain. The European Innovation Council’s instruments will be deployed in parallel to support early-stage fusion startups in maturing their technologies within the EU, while attracting external capital.

The strategic logic is not hard to follow. The EU’s electricity demand is forecast to double by 2050, driven by industrial electrification, electric mobility, and the rapid expansion of data centre capacity. Renewables and battery storage can absorb a significant portion of that growth, but baseload requirements in a decarbonised grid remain contested terrain. Fusion, if it reaches commercial scale before mid-century, offers something that wind and solar cannot: firm, dispatchable, carbon-free power at very high energy density. The EU’s stated ambition is to be the first jurisdiction to connect a commercial fusion power plant to the grid. That goal is aspirational; whether €222 million over two years closes the gap is a separate question.

How does the EU’s public fusion investment compare to the United States and China in the global race to commercialise fusion power?

The global private fusion investment landscape reveals the scale of the competitive challenge Brussels faces. According to data from the Fusion for Energy Observatory, total private sector investment in fusion reached approximately €13 billion globally, with the United States accounting for €6.9 billion, or roughly 53 percent of all funding, spread across 42 companies. China follows at €4.4 billion, or 34 percent, concentrated in eight companies, many of which benefit from state-directed capital. The US and China together account for approximately 86 percent of global private fusion funding, creating what analysts have characterised as a bipolar structure at the top of the market.

The EU’s private ecosystem, by contrast, consists of eight companies that have collectively raised approximately €712 million, or roughly five percent of global funding. Germany dominates within the bloc, with companies including Marvel Fusion and Proxima Fusion accounting for the lion’s share of European private fusion capital. The Fusion for Energy observatory noted that several US and Chinese fusion companies have already achieved unicorn valuations, including Commonwealth Fusion Systems at approximately €2.6 billion and China Fusion Energy at approximately €1.9 billion. No European fusion startup has reached equivalent scale.

There is a mitigating factor in this comparison that the raw private funding numbers obscure. The EU has invested approximately €6.8 billion through its Fusion for Energy Joint Undertaking in the industrial supply chain that supports ITER, building deep manufacturing capabilities in European companies for the complex components that fusion reactors require. That supply chain capability is a structural asset that private startup investment alone cannot replicate quickly. The question the new Public-Private Partnership is designed to answer is whether that industrial foundation can be redirected from research-phase procurement toward commercially competitive fusion power plant development at scale.

What does the €108 million fission allocation fund and how does it support the EU’s Small Modular Reactor strategy announced in March 2026?

The €108 million fission allocation covers a broad portfolio of nuclear safety, innovation, and skills priorities that complement the Commission’s parallel push on small modular reactors. Research under this stream will address the safe long-term operation of existing nuclear power plants across Europe, the safety frameworks required for advanced SMR designs and next-generation reactor concepts, and improvements in nuclear fuel and materials technology. The programme also funds research into the management of radioactive waste, which remains one of the most politically contested dimensions of nuclear energy across EU member states.

A less prominent but strategically significant element is the nuclear medicine allocation within the fission stream. The programme will fund research aimed at securing the EU’s domestic supply of medical radioisotopes used in novel nuclear medicine therapies, including treatments in oncology. European healthcare systems have faced periodic isotope supply disruptions tied to ageing research reactors and concentrated production infrastructure. Building out isotope production autonomy aligns with the EU’s broader industrial sovereignty agenda, and the Commission has framed this as a healthcare resilience priority rather than simply a research initiative.

The fission programme also explicitly targets the EU’s nuclear skills gap. Open access to more than 230 nuclear research facilities across member states will be facilitated, and Marie Sklodowska-Curie grants will be used to attract researchers from inside and beyond the EU. The programme additionally supports the integration of Ukrainian nuclear researchers into the European Research Area, a dimension that carries clear geopolitical intent as the EU seeks to maintain cooperative ties with Ukraine’s scientific community while Russian aggression continues to reshape European energy dependency concerns.

What execution risks and structural gaps could prevent the EU from achieving its ambition of being first to bring fusion to the grid?

The ambition embedded in the Euratom Work Programme is considerable, but the execution risks are real and not unique to the EU. Fusion has a long institutional history of underestimating timelines and engineering complexity, and ITER itself has absorbed significant schedule revisions and cost growth over its construction period. The new Public-Private Partnership is the right structural mechanism in principle, but its effectiveness depends on how quickly it can attract private co-investment at meaningful scale, how the governance framework handles intellectual property rights and technology licensing, and whether the regulatory environment can be adapted to accommodate commercial fusion timelines.

Analysis from the Clean Air Task Force has identified overlapping and competing governance structures within the EU fusion ecosystem as a material impediment to startup competitiveness. European fusion companies operate across multiple national regulatory regimes, and the EU lacks a unified fusion-specific regulatory pathway of the kind that could meaningfully accelerate the permitting and licencing processes that commercial deployment will eventually require. The upcoming EU Fusion Strategy, previewed in the Euratom programme as a near-term deliverable, will need to address this structural issue directly if the Public-Private Partnership is to function as intended.

There is also a question of capital adequacy. The €222 million fusion allocation across two years, while meaningful as a public-sector signal, is modest relative to the private capital flows that US and Chinese fusion companies have already attracted. The European Innovation Council’s instruments can leverage additional private investment, but the multiplier effect depends heavily on investor confidence in EU fusion policy continuity, regulatory predictability, and the depth of the industrial supply chain that will need to support commercial-scale construction. The Euratom programme’s two-year horizon, extended from the original 2021-2025 framework to bridge to the next multi-year EU budget, also introduces uncertainty about the longer-term funding trajectory that potential private co-investors will want to understand before committing capital.

How does the Euratom 2026-2027 programme fit into the broader EU nuclear policy reset under von der Leyen and Zaharieva?

The Euratom Work Programme adoption sits within a cluster of nuclear policy actions the European Commission has taken in rapid succession in early 2026. The SMR Strategy, presented by President von der Leyen at the Paris Nuclear Energy Summit on 10 March, set out the EU’s intention to develop domestically manufactured small modular reactors as part of its clean industrial agenda. The Community Nuclear Illustrative Programme, the Net-Zero Industry Act, and the Clean Industrial Deal collectively provide the policy scaffolding within which the Euratom programme operates. Commissioner Ekaterina Zaharieva, responsible for Startups, Research and Innovation, has framed the ambition explicitly as achieving first-mover status in commercial fusion, a claim that carries industrial policy weight beyond the energy sector.

The programme also feeds into a Draghi report-aligned agenda on European competitiveness. Mario Draghi’s 2024 report on the future of European competitiveness explicitly identified fusion as requiring a stable and predictable ecosystem for industrial innovation that leverages the ITER project and establishes a clear technology development roadmap. The Euratom programme’s Public-Private Partnership structure and its EUROfusion support are direct responses to that framing. Whether the Commission’s execution matches the ambition that Draghi’s diagnosis implied is the central question the next two years of the programme will begin to answer.

For European energy policy observers, the signal embedded in this programme extends beyond the specific funding allocations. It represents the EU formally treating fusion as an industrial policy priority rather than a long-horizon science project, which changes how private capital, member state governments, and industrial partners are likely to engage with the sector. If the Public-Private Partnership attracts meaningful co-investment in its first call cycle, the programme will have achieved something structurally significant. If the calls underwhelm, the gap between EU fusion ambition and the US and Chinese investment trajectories will continue to widen at an uncomfortable pace.

Key takeaways: What the EU’s €330 million Euratom investment means for the energy sector, nuclear industry, and fusion startups

• The European Commission has formally adopted the 2026-2027 Euratom Work Programme, allocating €222 million to fusion energy and €108 million to nuclear fission research, safety, and skills, framing both as industrial sovereignty priorities rather than pure science spending.
• A new European Public-Private Partnership for Fusion Energy is the programme’s centrepiece structural innovation, designed to attract private co-investment, develop commercially viable fusion technologies, and build a European fusion supply chain with the scale to compete globally.
• The competitive gap is material: the US holds approximately 53 percent and China approximately 34 percent of global private fusion investment, while EU-based private fusion companies have raised roughly five percent of global funding, a disparity the PPP mechanism is explicitly designed to address.
• The EU’s €6.8 billion ITER supply chain investment through Fusion for Energy represents an existing industrial asset that the new programme seeks to redirect toward commercial fusion applications, a transition that depends on governance reform as much as additional funding.
• Execution risks include governance fragmentation across member state regulatory regimes, the absence of a unified EU fusion licencing pathway, and the two-year horizon of the programme, which limits the long-term funding certainty that private co-investors require.
• The fission allocation supports SMR safety research, advanced reactor design, long-term operation of existing plants, and radioactive waste management, directly complementing the SMR Strategy von der Leyen presented at the Paris Nuclear Energy Summit in March 2026.
• Medical radioisotope supply autonomy is an underappreciated element of the programme, addressing a genuine healthcare resilience risk that has caused periodic supply disruptions in EU oncology and diagnostic medicine.
• The programme integrates Ukrainian nuclear researchers into the European Research Area, a geopolitically deliberate decision that extends scientific cooperation with Kyiv at a moment of continued energy vulnerability across the continent.
• Open access to more than 230 nuclear research facilities across the EU, combined with Marie Sklodowska-Curie mobility grants and the European Nuclear Skills Academy, signals that talent pipeline development is being treated as a strategic constraint, not a secondary concern.
• The upcoming EU Fusion Strategy, signalled as a near-term Commission deliverable, will need to resolve the governance, regulatory, and industrial policy questions that the Euratom Work Programme raises but cannot by itself answer.